Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew W Mulcahy

Showing results (1-10 of 32) with videos related to

Pageof 4
Sort By:
Rand Health Quarterly|June 10, 2024
Comparing New Prescription Drug Availability and Launch Timing in the United States and Other OECD CountriesAndrew W Mulcahy
Health Affairs (Project Hope)|April 6, 2026
'Most Favored Nation' Drug Pricing: An Idea To What End?Andrew W Mulcahy
Rand Health Quarterly|June 10, 2024
Comparing Insulin Prices in the United States to Other Countries: Updated Results Using 2022 DataAndrew W Mulcahy, Daniel Schwam
Rand Health Quarterly|July 15, 2022
Prescription Drug Supply Chains: An Overview of Stakeholders and RelationshipsAndrew W Mulcahy, Vishnupriya Kareddy
Health Affairs (Project Hope)|August 19, 2016
Gaining Coverage Through Medicaid Or Private Insurance Increased Prescription Use And Lowered Out-Of-Pocket SpendingAndrew W Mulcahy, Christine Eibner, Kenneth Finegold
JAMA Internal Medicine|July 18, 2018
Associations Between the Patient Protection and Affordable Care Act Medicaid Primary Care Payment Increase and Physician Participation in MedicaidAndrew W Mulcahy, Tadeja Gracner, Kenneth Finegold
Rand Health Quarterly|June 10, 2024
International Prescription Drug Price Comparisons: Estimates Using 2022 DataAndrew W Mulcahy, Daniel Schwam, Susan L Lovejoy
Health Affairs (Project Hope)|August 9, 2011
Setting cost-effectiveness thresholds as a means to achieve appropriate drug prices in rich and poor countriesPatricia M Danzon, Adrian Towse, Andrew W Mulcahy
Rand Health Quarterly|August 8, 2018
Biosimilar Cost Savings in the United States: Initial Experience and Future PotentialAndrew W Mulcahy, Jakub P Hlavka, Spencer R Case
Health Economics|December 3, 2013
Pharmaceutical pricing in emerging markets: effects of income, competition, and procurementPatricia M Danzon, Andrew W Mulcahy, Adrian K Towse
Pageof 4

Showing results (1-10 of 32) with videos related to

Sort By:
Pageof 4
Rand Health Quarterly|June 10, 2024
Comparing New Prescription Drug Availability and Launch Timing in the United States and Other OECD CountriesAndrew W Mulcahy
Health Affairs (Project Hope)|April 6, 2026
'Most Favored Nation' Drug Pricing: An Idea To What End?Andrew W Mulcahy
Rand Health Quarterly|June 10, 2024
Comparing Insulin Prices in the United States to Other Countries: Updated Results Using 2022 DataAndrew W Mulcahy, Daniel Schwam
Rand Health Quarterly|July 15, 2022
Prescription Drug Supply Chains: An Overview of Stakeholders and RelationshipsAndrew W Mulcahy, Vishnupriya Kareddy
Health Affairs (Project Hope)|August 19, 2016
Gaining Coverage Through Medicaid Or Private Insurance Increased Prescription Use And Lowered Out-Of-Pocket SpendingAndrew W Mulcahy, Christine Eibner, Kenneth Finegold
JAMA Internal Medicine|July 18, 2018
Associations Between the Patient Protection and Affordable Care Act Medicaid Primary Care Payment Increase and Physician Participation in MedicaidAndrew W Mulcahy, Tadeja Gracner, Kenneth Finegold
Rand Health Quarterly|June 10, 2024
International Prescription Drug Price Comparisons: Estimates Using 2022 DataAndrew W Mulcahy, Daniel Schwam, Susan L Lovejoy
Health Affairs (Project Hope)|August 9, 2011
Setting cost-effectiveness thresholds as a means to achieve appropriate drug prices in rich and poor countriesPatricia M Danzon, Adrian Towse, Andrew W Mulcahy
Rand Health Quarterly|August 8, 2018
Biosimilar Cost Savings in the United States: Initial Experience and Future PotentialAndrew W Mulcahy, Jakub P Hlavka, Spencer R Case
Health Economics|December 3, 2013
Pharmaceutical pricing in emerging markets: effects of income, competition, and procurementPatricia M Danzon, Andrew W Mulcahy, Adrian K Towse
Pageof 4